担当区分：筆頭著者,　責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

INTRODUCTION: Metastatic iris tumors from lung cancer are uncommon and challenging to diagnose. As lung cancer treatments improve, life expectancy increases, potentially leading to more cases of metastasis. These tumors often cause neovascular glaucoma, making intraocular pressure (IOP) management crucial, especially in terminal-stage patients. CASE PRESENTATION: A 65-year-old man with small cell lung carcinoma (SCLC) presented with right ocular pain and blurred vision. His right IOP was 55 mm Hg, and examination revealed anterior chamber cells, multiple grayish-white iris masses, and right iris neovascularization. Anterior chamber fluid cytology confirmed the diagnosis of metastatic iris tumors from SCLC. Despite treatment with topical eye drops, oral acetazolamide, and intravenous hypertonic mannitol, the IOP remained poorly controlled. Intravitreal aflibercept was subsequently administered into his right eye for neovascular glaucoma. Neovascular glaucoma disappeared rapidly, but IOP did not improve. However, intravenous infusion of hypertonic mannitol was no longer required, and the complaints of nausea associated with IOP decreased. Although this patient died 4 months after the initial visit due to multiple metastases of SCLC, the intravitreal aflibercept was effective in shrinking the iris tumor size and lowering IOP in the terminal phase of the disease. CONCLUSION: This is the first reported use of intravitreal aflibercept for SCLC metastases to the iris. While the prognosis of patients with metastatic iris tumors remains poor, intravitreal aflibercept injections show potential in reducing iris tumor size and lowering IOP. Although not curative, this therapeutic approach may play a significant role in the symptom management of these patients.

DOI： 10.1159/000544159

PubMed

researchmap

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

Alkaline burns to the cornea lead to loss of corneal transparency, which is essential for normal vision. We used a rat corneal alkaline burn model to investigate the effect of ophthalmic trimebutine solution on healing wounds caused by alkaline burns. Trimebutine, an inhibitor of the high-mobility group box 1-receptor for advanced glycation end products, when topically applied to the burned cornea, suppressed macrophage infiltration in the early phase and neutrophil infiltration in the late phase at the wound site. It also inhibited neovascularization and myofibroblast development in the late phase. Furthermore, trimebutine effectively inhibited interleukin-1β expression in the injured cornea. It reduced scar formation by decreasing the expression of type III collagen. These findings suggest that trimebutine may represent a novel therapeutic strategy for corneal wounds, not only through its anti-inflammatory effects but also by preventing neovascularization.

DOI： 10.1038/s41598-024-61112-4

PubMed

researchmap

担当区分：筆頭著者  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：眼科臨床紀要会  

researchmap

担当区分：筆頭著者   記述言語：日本語   出版者・発行元：(公社)日本眼科手術学会  

目的:テクニスアイハンスオプティブルーSimplicity(DIB00V,AMOジャパン社)の異なる目標屈折度数による早期使用成績を検討する.方法:対象は善行すずき眼科においてDIB00Vを用いた合併症のない白内障手術施行眼44例44眼である.目標度数を0Dとした群を0D群(23例23眼),-1Dとした群を-1D群(21例21眼)として,後ろ向きに検討した.検討項目は術後1ヵ月後の矯正遠方視力,遠方,100cm,70cm,50cm,40cm,30cmの裸眼視力である.角膜乱視1D以内の症例を適応とした.結果:矯正遠方視力に有意差はなかった.裸眼遠方視力(logMAR)は0D群で0.03±0.12,-1D群で0.28±0.31と有意に0D群がよかった(p<0.001,unpaired t-test).一方,40cm,50cmでは-1D群のほうが有意によかった(p<0.05,unpaired t-test).30cm,70cm,100cmに有意差はなかった.結論:DIB00Vは患者の要望により目標度数を工夫することによって,中間から近方視力の向上も期待できる可能性がある.(著者抄録)

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公財)日本眼科学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公社)日本眼科手術学会  

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(公財)日本眼科学会  

J-GLOBAL

researchmap

researchmap